Literature DB >> 22371888

Daptomycin versus vancomycin in a methicillin-resistant Staphylococcus aureus endophthalmitis rabbit model: bactericidal effect, safety, and ocular pharmacokinetics.

Sophie Lefèvre1, Maher Saleh, Luc Marcellin, Audrey Subilia, Tristan Bourcier, Gilles Prévost, François Jehl.   

Abstract

Staphylococcus aureus is a frequent cause of acute endophthalmitis, and infection with this virulent bacterium is often associated with a poor visual outcome. In this study, we investigated the bactericidal efficacy and the safety of intravitreal daptomycin (DAP), a lipopeptide antibiotic with broad-spectrum activity against Gram-positive bacteria, compared with those of intravitreal vancomycin (VAN) in a methicillin-resistant S. aureus endophthalmitis rabbit model. The pharmacokinetics and pharmacodynamics of daptomycin in the infected eyes were also studied. Rabbits were randomly divided into three treatment groups (n = 8) and one untreated group (n = 4), to compare the effect of single intravitreal injections of 0.2 mg and 1 mg of daptomycin (DAP 0.2 and DAP 1 groups, respectively) with that of 1 mg of intravitreal vancomycin (VAN 1 group). Vitreal aspirates were regularly collected and grading of ocular inflammation was regularly performed until euthanasia on day 7. In the DAP 0.2 group, 62.5% of the eyes were sterilized and the mean bacterial count presented a reduction of 1 log unit. In the DAP 1 and VAN 1 groups, the infection was eradicated (100% and 87.5% of eyes sterilized, respectively), with a 4-log-unit reduction of the mean bacterial count. The bactericidal efficacy in the DAP 1 group was not inferior to that in the VAN 1 group and was superior to that of the other regimens in limiting the ocular inflammation and preserving the architecture of the ocular structures (P < 0.05). The elimination half-life (t(1/2β)) of daptomycin was independent of the administered dose (38.8 ± 16.5 h and 40.9 ± 6.7 h, respectively, for the DAP 0.2 and DAP 1 groups) and was significantly longer than the t(1/2β) of vancomycin (20.5 ± 2.0 h for the VAN 1 group) (P < 0.05). This antibiotic could therefore be considered for the treatment of intraocular infections caused by Gram-positive bacteria.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22371888      PMCID: PMC3346597          DOI: 10.1128/AAC.05745-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Postoperative endophthalmitis: incidence, predisposing surgery, clinical course and outcome.

Authors:  S Somani; A Grinbaum; A R Slomovic
Journal:  Can J Ophthalmol       Date:  1997-08       Impact factor: 1.882

2.  Comparison of Tn1546-like elements in vancomycin-resistant Staphylococcus aureus isolates from Michigan and Pennsylvania.

Authors:  Nancye C Clark; Linda M Weigel; Jean B Patel; Fred C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

3.  Severe bacterial endophthalmitis: towards improving clinical outcomes.

Authors:  Billy D Novosad; Michelle C Callegan
Journal:  Expert Rev Ophthalmol       Date:  2010-10

4.  Epidemiology of infective endophthalmitis in France. The French Collaborative Study Group on Endophthalmitis.

Authors:  A Fisch; A Salvanet; T Prazuck; F Forestier; L Gerbaud; G Coscas; C Lafaix
Journal:  Lancet       Date:  1991-11-30       Impact factor: 79.321

5.  Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance.

Authors:  J Blaser; B B Stone; M C Groner; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

6.  Postoperative endophthalmitis: a comparison of methods for treatment and prophlaxis with gentamicin.

Authors:  G A Peyman; J T Paque; H I Meisels; T O Bennett
Journal:  Ophthalmic Surg       Date:  1975

7.  Effect of intravitreal dexamethasone in treatment of pneumococcal endophthalmitis in rabbits.

Authors:  S S Park; N Samiy; K Ruoff; D J D'Amico; A S Baker
Journal:  Arch Ophthalmol       Date:  1995-10

8.  Pharmacokinetics and ocular penetration of grepafloxacin in albino and pigmented rabbits.

Authors:  S Perez; C Solans; M A Bregante; I Pinilla; M A García; F Honrubia
Journal:  J Antimicrob Chemother       Date:  2002-10       Impact factor: 5.790

9.  Spectrum of eye disease caused by methicillin-resistant Staphylococcus aureus.

Authors:  Julie Freidlin; Nisha Acharya; Thomas M Lietman; Vicky Cevallos; John P Whitcher; Todd P Margolis
Journal:  Am J Ophthalmol       Date:  2007-08       Impact factor: 5.258

10.  Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006.

Authors:  Dawn M Sievert; James T Rudrik; Jean B Patel; L Clifford McDonald; Melinda J Wilkins; Jeffrey C Hageman
Journal:  Clin Infect Dis       Date:  2008-03-01       Impact factor: 9.079

View more
  3 in total

1.  Low prevalence of tissue detection of cefepime and daptomycin used as empirical treatment during revision for periprosthetic joint infections: results of a prospective multicenter study.

Authors:  O Robineau; E Talagrand-Reboulh; B Brunschweiler; F Jehl; E Beltrand; F Rousseau; N Blondiaux; A Grillon; C Joseph; P Lambotte; P Boyer; Eric Senneville
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-05-20       Impact factor: 3.267

2.  Controlled Release of Vancomycin From a Thermoresponsive Hydrogel System for the Prophylactic Treatment of Postoperative Acute Endophthalmitis.

Authors:  Emily Dosmar; Wenqiang Liu; Geeya Patel; Alison Rogozinski; William F Mieler; Jennifer J Kang-Mieler
Journal:  Transl Vis Sci Technol       Date:  2019-06-27       Impact factor: 3.283

3.  Intravitreal Daptomycin for Recalcitrant Postoperative Endophthalmitis.

Authors:  Jennifer M Sim; Kapil G Kapoor; Alan L Wagner
Journal:  Case Rep Ophthalmol       Date:  2016-02-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.